Corvus Pharmaceuticals (CRVS) Competitors $3.37 +0.02 (+0.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.44 +0.07 (+2.20%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. CALT, AUPH, GYRE, SNDX, ADPT, SYRE, SPRY, NRIX, ELVN, and NTLAShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Gyre Therapeutics Syndax Pharmaceuticals Adaptive Biotechnologies Spyre Therapeutics ARS Pharmaceuticals Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends. Which has more volatility and risk, CALT or CRVS? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Is CALT or CRVS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Corvus Pharmaceuticals' return on equity of -70.71% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Corvus Pharmaceuticals N/A -70.71%-45.90% Which has higher earnings and valuation, CALT or CRVS? Corvus Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Corvus PharmaceuticalsN/AN/A-$27.03M-$0.93-3.62 Do analysts prefer CALT or CRVS? Calliditas Therapeutics AB (publ) presently has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Corvus Pharmaceuticals has a consensus target price of $15.67, suggesting a potential upside of 364.89%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media refer more to CALT or CRVS? In the previous week, Corvus Pharmaceuticals had 19 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 19 mentions for Corvus Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Corvus Pharmaceuticals' average media sentiment score of 0.24 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Corvus Pharmaceuticals Neutral Do institutionals and insiders believe in CALT or CRVS? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CALT or CRVS? Corvus Pharmaceuticals received 266 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 62.08% of users gave Corvus Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Corvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% SummaryCorvus Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks. Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$216.55M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-3.627.2024.5919.03Price / SalesN/A225.82383.9393.17Price / CashN/A65.6738.1634.64Price / Book4.276.476.944.33Net Income-$27.03M$141.90M$3.20B$247.06M7 Day Performance-19.95%-3.02%-2.30%-0.53%1 Month Performance-14.47%-4.63%3.07%-3.74%1 Year Performance88.27%-8.61%11.15%1.72% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.3133 of 5 stars$3.37+0.6%$15.67+364.9%+88.3%$216.55MN/A-3.6230Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.9846 of 5 stars$8.40+2.9%$11.50+36.9%+69.2%$1.15B$235.13M-56.00300Analyst UpgradePositive NewsGYREGyre Therapeutics0.2 of 5 stars$12.28+1.4%N/A-48.1%$1.15B$105.03M0.0040News CoverageSNDXSyndax Pharmaceuticals3.5468 of 5 stars$13.04+0.7%$36.00+176.1%-41.2%$1.12B$23.68M-3.59110Positive NewsADPTAdaptive Biotechnologies3.3801 of 5 stars$7.54+3.6%$9.10+20.7%+184.4%$1.12B$178.96M-6.92790SYRESpyre Therapeutics2.0271 of 5 stars$18.54+2.8%$54.83+195.8%-52.2%$1.12B$890,000.00-2.48100News CoverageSPRYARS Pharmaceuticals3.3282 of 5 stars$11.44-3.6%$31.00+171.0%+26.8%$1.11B$2.57M-22.4390Analyst RevisionNRIXNurix Therapeutics2.0442 of 5 stars$13.93+2.5%$30.88+121.7%-13.7%$1.06B$54.55M-4.82300ELVNEnliven Therapeutics2.8728 of 5 stars$21.04+1.4%$38.25+81.8%+15.5%$1.03BN/A-11.0750News CoverageNTLAIntellia Therapeutics4.4793 of 5 stars$9.58+4.8%$37.56+292.0%-68.9%$991.69M$57.88M-1.76600Analyst Revision Remove Ads Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives Gyre Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Spyre Therapeutics Alternatives ARS Pharmaceuticals Alternatives Nurix Therapeutics Alternatives Enliven Therapeutics Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts